search icon
      blog search icon

      Why CNS Pharmaceuticals, Inc. (CNSP) stock is Climbing in Pre-Market today? - Stocks Telegraph

      By ST Staff

      Published on

      June 18, 2021

      12:36 PM UTC

      Last Updated on

      July 14, 2021

      11:17 AM UTC

      Why CNS Pharmaceuticals, Inc. (CNSP) stock is Climbing in Pre-Market today? - Stocks Telegraph

      Shares of the CNS Pharmaceuticals, Inc. (CNSP) stock were climbing in the Pre-market today on June 18, 2021, following the announcement made by CNS pharmaceuticals yesterday that it has been selected to be included in Russell 2000® Index. The CNSP stock price saw a push of 4.00% to reach $2.08 a share at the time of this writing. CNSP stock climbed 3.09% at the previous closing. Let’s take a closer look at current happenings.

      What’s Happening?

      CNS Pharmaceuticals, Inc, founded in 2017, develops the anticancer drugs that are used to treat brain and central nervous system tumors. CNSP addition in Russell 2000® Index would be effective from after closing of U.S. equity markets on June 25, 2021. This inclusion would help the CNSP stock to drive market awareness for its clinical program in the fight against glioblastoma multiforme (GBM) disease.

      The Russell 2000® Index is the subset of the Russell 3000® Index in which  2,000 smallest securities based on current index membership and market cap combination are added. It evaluates the performance of these smallest securities and constitutes  10% of the total market capitalization of its parent index.

      Patient Enrollment:

      Back to the previous month on May 19, 2021, CNSP stock did announce the commencing of patient enrollment in its potential pivotal study that was intended to evaluate the efficacy as well as safety of Berubicin when it is used to treat adult recurrent Glioblastoma Multiforme (GBM). The CNS pharmaceuticals planned 210 patients in its 35 clinical sites in the United States and also expressed the wish to extend the trial in Western Europe. The primary endpoint for the study was overall survival.

      Financial View of CNSP stock:

      On May 14, 2021, CNSP stock released its first-quarter 2021 financial results according to which a $3.6 million net loss was reported higher than $2.0 million in the same quarter of the previous year. Research and development expenses increased by $1.6 million in the recently reported quarter to reach $2.2 million as compared to the same prior-year period. The quarter ended with $11.0 million cash and cash equivalents which according to CNSP stock’s management is enough to fund operation during the current year.


      The CNSP stock is continuing the rising momentum after the announcement of its selection in the Russell 2000® Index. The stock is growing with time and has enough cash to fund its operations for next year. Hence investors need to keep this stock on their books.

      More From Stocks telegraph